ProMIS Neurosciences (PMN) Fundamental Analysis: Revenue, Earnings & Valuation

3.00 / 10

Underperform

Fundamental rating is Underperform with a 3/10 score. Strengths include Cash‑MV and high inventory turnover; weaknesses are low PB‑ROE, negative Asset‑MV, and weak Revenue‑MV. Overall financial health appears challenged.

Analysis Checks(5/10)

Revenue-MV

Value-0.11

Score1/3

Weight17.48%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight4.52%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight23.19%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.64%

1M Return-0.63%

PB-ROE

Value23.30

Score0/3

Weight11.67%

1M Return3.23%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-1.34%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.99%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight13.42%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight9.11%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight20.60%

1M Return5.94%

Is PMN undervalued or overvalued?

PMN scores 3.00/10 on fundamentals and holds a Premium valuation at present. Backed by its -521.61% ROE, 0.00% net margin, -2.82 P/E ratio, -89.14 P/B ratio, and -943.66% earnings growth, these metrics solidify its Underperform investment rating.